Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01860339 · ClinicalTrials.gov registry record
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
A clinical trial of Huntington's Disease, sponsored by Peggy C Nopoulos.
- Recruiting
- Registry status
- 400
- Enrollment target
- 6
- Study locations
NCT01860339 is a study of Huntington's Disease that is actively recruiting participants, run by Peggy C Nopoulos. The registered enrollment target is 400 participants, below the 4,744-participant average among 8 other Huntington's Disease trials with a reported enrollment target (92% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT01860339, a study of Huntington's Disease, is actively recruiting participants, sponsored by Peggy C Nopoulos.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 6
- Study locations
Study Summary
Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat (CAG)expansion in the gene Huntingtin (HTT). This disease has classically been conceptualized as a neurodegenerative disease. However, recent evidence suggests that abnormal brain development may play an important role in the etiology of HD. Huntingtin (HTT)is expressed during development and through life. In animal studies, the HTT gene has been shown to be vital for brain development. This suggests that a mutant form of HTT (gene-expanded or CAG repeats of 40 and above) would affect normal brain development. In addition, studies in adults who are gene-expanded for HD, but have not yet manifested the illness, (pre-HD subjects) have significant changes in the structure of their brain, even up to 20 years before onset of clinical diagnosis. How far back these changes are evident is unknown. One possibility is that these brain changes are present throughout life, due to changes in brain development,though initially associated with only subtle functional abnormalities. In an effort to better understand the developmental aspects of this brain disease, the current study proposes to evaluate brain structure and function in children, adolescents, and young adults (ages 6-30) who are at risk for developing HD - those who have a parent or grandparent with HD. Brain structure will be evaluating using Magnetic Resonance Imaging (MRI) with quantitative measures of the entire brain, cerebral cortex, as well as white matter integrity via Diffusion Tensor Imaging. Brain function will be assessed by cognitive tests, behavioral assessment, and physical and neurologic evaluation. Subjects that are gene-expanded (GE) will be compared to subjects who are gene non-expanded (GNE). Changes in brain structure and/or function in the GE group compared to the GNE group would lend support to the notion that this disease has
Conditions Studied
Study Locations (6)
California
- University of California Davis - Sacramento
Iowa
- University of Iowa Hospitals and Clinics, Department of Psychiatry - Iowa City
New York
- Columbia University Medical Center - New York
Pennsylvania
- Children's Hospital of Philadelphia with the University of Pennsylvania - Philadelphia
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2005-07 |
| Est. Completion | 2026-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01860339
The ClinicalTrials.gov registry entry for NCT01860339 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,744-participant average among 8 other Huntington's Disease trials with a reported enrollment target (92% lower). The listed sponsor is Peggy C Nopoulos, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Huntington's Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01860339 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Iowa, New York.
Frequently Asked Questions
What is clinical trial NCT01860339 about?
NCT01860339 is a clinical study titled "Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease". Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat (CAG)expansion in the gene Huntingtin (HTT). This disease has classically been conceptualized as a neurodegenerative disease. How...
What is the current status of trial NCT01860339?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2005-07. Estimated completion is 2026-08-31.
What conditions does trial NCT01860339 study?
This clinical trial studies the following conditions: Huntington's Disease.
Who is sponsoring clinical trial NCT01860339?
This trial is sponsored by Peggy C Nopoulos, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01860339 being conducted?
This trial has 6 study locations across California, Iowa, New York, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
RECRUITING
-
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
RECRUITING
-
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
COMPLETED · Phase 1
-
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
COMPLETED · Phase 2
-
FuRST 2.0 Cognitive Pre-Testing
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.